Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

George Sigounas named the first-ever chief science advisor at NCI

George Sigounas, an expert in bone marrow transplantation, was named to the newly created post of chief science advisor at NCI.

Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted

Congressional Justifications displaying the details of the President Trump’s budget request for the fiscal year 2026 show that the success rates for Research Project Grants at NCI would plummet from 13.4% in FY2024 to 8.3% during the next fiscal year.

FDA booth stood empty at 2025 ASCO annual meeting

Booth 10025 became an unlikely crowd magnet at the exhibit hall at the annual meeting of the American Society of Clinical Oncology that ended earlier this week.

ALT GOV: The HHS “resistance” on social media

After a sequence of events that unfolded publicly on NCI’s Instagram feed May 28, RIFed and “retired” members of the NCI communications team took to the independent social media platform BlueSky, creating an alternative and anonymous social media presence.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Drugs & Targets

China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer

The National Medical Products Administration in China approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

June 06, 2025

Vol.51 No.22

Clinical Trials & Tribulations

Surviving cancer is often not a patient’s most challenging battle

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

May 30, 2025

Vol.51 No.21

By Boris C. Pasche